|
10 Mio. USD Meilensteinzahlung von Amgen - der bispezifische Antikörper AMG 424 (CD38xCD3) wird in Konkurrenz treten zu Daratumumab, MOR208 und isatuximab. MONROVIA, Calif., Dec. 5, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the Company has earned a $10 million milestone payment from Amgen. The payment is triggered by the submission of the Investigational New Drug (IND) Application for AMG 424, a novel humanized T cell-recruiting bispecific antibody targeting CD38 and CD3, which uses Xencor's Bispecific XmAb\u00ae Technology. Xencor, Inc. Logo "XmAb antibody Fc domains continue to enable our partners to create a broad range of drug candidates, in addition to driving our internal programs," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. "Our XmAb Fc domains, each providing unique functional improvements to antibodies, open the door to new targets and new biology previously difficult to access. By selectively licensing our XmAb technology, we believe we create value in non-core areas, while we focus on advancing our key internal development programs." Entered in September 2015, the agreement with Amgen licensed the use of XmAb Bispecific technology for five internal Amgen programs, as well as the Xencor preclinical bispecific T cell engager program directed at CD38 and CD3 for multiple myeloma. |
|
| aus der Diskussion: | Antikörper-Optimierung durch Xencor |
| Autor (Datum des Eintrages): | Joschka Schröder (05.12.17 14:44:01) |
| Beitrag: | 75 von 268 (ID:56368273) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |